The trajectory of Sildenafil presents a intricate picture for those considering investment. While the initial launch generated substantial profits, the lapse of its patent opened the door to cheaper versions, dramatically eroding sales. This presents a specific dilemma for pharmaceutical companies depending on similar blockbuster medications, sugge

The story of Viagra, and its parent company copyright, presents a challenging case study for investors. Initially a blockbuster drug, generating billions in income, its exclusivity period created a deluge of lower-priced alternatives , significantly eroding its market share . While certain firms may attempt to capitalize on similar conditions , the